BioInformant

Your Global Leader in Stem Cell Market Research

Home » cell therapy » Page 13

Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

By 1 Comment

Pluristem TherapeuticsI had the honor of interviewing Dr. Racheli Ofir, Vice President (VP) of Research & Intellectual Property at Pluristem Therapeutics. Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

The company is at the forefront of placental-based cell therapy applications. In addition to other accomplishments, the company is now preparing for a proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI).

Interview with Dr. Racheli Ofir, VP of Research & IP at Pluristem Therapeutics

Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics
Dr. Racheli Ofir

Cade Hildreth: What is your background and how did you get involved with Pluristem?

Dr. Racheli Ofir:  I did my PhD and post-doc in cellular and developmental biology at the Technion in Haifa. I joined Pluristem 9 years ago and am responsible for the research activity of the company including efficacy and safety studies of Pluristem placenta-derived cells, as well as revealing the underlying mechanism of action of the cells. [Read more…]

Mesenchymal Stem Cell (MSC) Company Cynata Therapeutics Reports Nearly $1 Million R&D Tax Incentive Refund

By Leave a Comment

In major news released today, Cynata Therapeutics announced that it is receiving a R&D Tax Incentive refund of nearly $1 million for the 2014/2015 financial year.

This cash influx will assist the company with the upcoming clinical trial involving its Cymerus™ mesenchymal stem cell (MSC) product, CYP-001. Cynata’s Cymerus™ MSCs are derived from a single donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. Not only does this approach allows MSCs to be produced in nearly limitless quantities, it also eliminates product variability and allows for lower manufacturing costs.

Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw.  To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

By Leave a Comment

Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).

To learn  more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]

Mesenchymal Stem Cell (MSC), Regenerative Medicine (RM), and Cell Therapy (CT) Market Research

By Leave a Comment

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications. [Read more…]

Preparations Begin for Phase II Stem Cell Trial for Multiple Sclerosis (MS)

By Leave a Comment

For patients with multiple sclerosis (MS), the Tisch MS Research Center of New York (MSRCNY) and its affiliated clinical practice, the International Multiple Sclerosis Management Practice, are important centers. They represent one of the few sites worldwide were clinical excellence is paired with cutting-edge research aimed at finding a cure for MS, a disease which affects 400,000 Americans and 2.5 million people worldwide.

In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced that it is pursuing a Phase II clinical trial, exploring the use of spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of MS.  [Read more…]

BioInformant's World-Class Clients